A multicenter look at gene therapy for spinal muscular atrophy
In May 2019, the U.S. Food and Drug Administration (FDA) approved a gene replacement therapy for the inherited, progressive neuromuscular disease 5q-linked spinal muscular atrophy (SMA). Approval included all children with ...
Aug 25, 2020
0
2